Does rectal diclofenac reduce post-ERCP pancreatitis? A district general hospital experience

IntroductionThere is controversy in the literature recently regarding the efficacy of rectal non-steroidal anti-inflammatory drugs (NSAID) to prevent post-ERCP pancreatitis (PEP). The aim of this study was to compare the incidence of PEP in three distinct groups of patients at the Royal United Hospi...

Full description

Saved in:

Bibliographic Details
Published in:	Frontline gastroenterology Vol. 9; no. 1; pp. 73 - 77
Main Authors:	Sheiybani, Giovanna, Brydon, Peter, Toolan, Miriam, Linehan, John, Farrant, Mark, Colleypriest, Benjamin
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group LTD 01-01-2018 BMJ Publishing Group
Series:	Research
Subjects:	Endoscopy Gastroenterology Meta-analysis Nonsteroidal anti-inflammatory drugs Pancreatitis Pancreatobiliary Performance evaluation Prevention Systematic review United Kingdom > UK Endoscopic Retrograde Pancreatography Pancreatitis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	IntroductionThere is controversy in the literature recently regarding the efficacy of rectal non-steroidal anti-inflammatory drugs (NSAID) to prevent post-ERCP pancreatitis (PEP). The aim of this study was to compare the incidence of PEP in three distinct groups of patients at the Royal United Hospital, Bath: no use of rectal diclofenac, selective use and blanket use without contraindication.MethodReadmission data, blood results, radiology reports and discharge summaries were used to identify patients with PEP from August 2010 to December 2015. The administration of rectal diclofenac postprocedure was recorded from the endoscopy reporting system.Results1318 endoscopic retrograde cholangiopancreatographies (ERCP) were performed by four endoscopists during the study period with 66 (5.0%) cases of pancreatitis. 445 ERCPs were performed prior to the introduction of NSAID use during which time, with an incidence of 35 (7.9%) episodes of PEP. During the selective period of NSAID use (high-risk patients) 539 ERCPs were performed and 72 (13.4%) patients received NSAIDs. 17 (3.2%) developed PEP. 334 ERCPs were performed when NSAIDs were given to all patients without contraindication. 289 (86.5%) of patients received rectal diclofenac and 13 (3.9%) developed pancreatitis. There is a statistically significant decrease in PEP comparing the groups of patients receiving NSAIDs selectively (p=0.0009) or routinely (p=0.0172) when compared with none. There is no difference between the selective and routine group (p=0.571).ConclusionOur data demonstrate that the introduction of a selective or routine use of NSAIDs for PEP in a District General Hospital (DGH) significantly decreases the risk of pancreatitis (risk reduction 43.7%).
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2041-4137 2041-4145
DOI:	10.1136/flgastro-2017-100832